Mimosa 5 Special Precautions

If any improvement in gastrointestinal symptoms does not occur after approximately 2 weeks of therapy, then this agent should not be continued without supervision.
Mosapride should be administered with care in elderly patients. Safety of this drug in children has not been established.
Severe (including fatal) hepatotoxicity has been rarely reported with use. Discontinue immediately if early signs/symptoms of hepatic toxicity or elevated liver enzymes occur.
Use with caution in situations where stimulated gastrointestinal (GI) motility may be dangerous, including mechanical GI obstruction, perforation, or hemorrhage.
Some prokinetic agents (eg, cisapride, domperidone, levosulpride, metoclopramide) are contraindicated. Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy.
Use in Pregnancy & Lactation: Mosapride use during pregnancy and lactation should be avoided.
Use in Children: Safety of this drug in children has not been established.
Use in the Elderly: Since in the elderly patients their physiological function in the kidneys and the liver are reduced in general, this drug should be administered with care by monitoring patients' condition. If any adverse reactions are found, appropriate measures such as reducing the dose (e.g. to 7.5 mg daily) should be given.